SMART precision cancer medicine: a FHIR-based app to provide genomic information at the point of care

Jeremy L. Warner, Matthew J. Rioth, Kenneth D. Mandl, Joshua C. Mandel, David Kreda, Isaac S. Kohane, Daniel Carbone, Ross Oreto, Lucy Lu Wang, Shilin Zhu,

Journal of the American Medical Informatics Association · 2016 · 71 citations · 24 references

DOIFull text

Open access

Concepts

TL;DR

Precision cancer medicine requires ready access to genomic data within clinical workflows and tools for interpretation, and the app can be deployed on any SMART on FHIR‑enabled EHR and evolve with external knowledge bases. The authors developed an EHR‑agnostic, clinico‑genomic mobile app to demonstrate point‑of‑care features and provide open‑source software that presents individual patients within the population‑level spectrum of cancer somatic.

Abstract

Abstract Background Precision cancer medicine (PCM) will require ready access to genomic data within the clinical workflow and tools to assist clinical interpretation and enable decisions. Since most electronic health record (EHR) systems do not yet provide such functionality, we developed an EHR-agnostic, clinico-genomic mobile app to demonstrate several features that will be needed for point-of-care conversations. Methods Our prototype, called Substitutable Medical Applications and Reusable Technology (SMART)® PCM, visualizes genomic information in real time, comparing a patient’s diagnosis-specific somatic gene mutations detected by PCR-based hotspot testing to a population-level set of comparable data. The initial prototype works for patient specimens with 0 or 1 detected mutation. Genomics extensions were created for the Health Level Seven® Fast Healthcare Interoperability Resources (FHIR)® standard; otherwise, the prototype is a normal SMART on FHIR app. Results The PCM prototype can rapidly present a visualization that compares a patient’s somatic genomic alterations against a distribution built from more than 3000 patients, along with context-specific links to external knowledge bases. Initial evaluation by oncologists provided important feedback about the prototype’s strengths and weaknesses. We added several requested enhancements and successfully demonstrated the app at the inaugural American Society of Clinical Oncology Interoperability Demonstration; we have also begun to expand visualization capabilities to include cancer specimens with multiple mutations. Discussion PCM is open-source software for clinicians to present the individual patient within the population-level spectrum of cancer somatic mutations. The app can be implemented on any SMART on FHIR-enabled EHRs, and future versions of PCM should be able to evolve in parallel with external knowledge bases.

References

24